(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
1 October 2009 (01.10.2009)

PCT

(10) International Publication Number
WO 2009/120927 A3

(51) International Patent Classification:
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/US2009/038509

(22) International Filing Date:
27 March 2009 (27.03.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/040,363 28 March 2008 (28.03.2008) US

(71) Applicant *(for all designated States except US)*: **SMITHKLINE BEECHAM CORPORATION** [US/US]; One Franklin Plaza, P.o. Box 7929, Philadelphia, PA 19101 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **HARGREAVE, Fredrick, E.** [CA/CA]; St. Joseph's Healthcare, 50 Charlton Avenue East, Hamilton, ON ON L8N 4A6 (CA). **VENTRESCA, Giampietro** [IT/GB]; Gunnels Wood Road, Stevenage, Hertforshire SG1 2NY (GB).

(74) Agents: **LOCKENOUR, Andrea, V.** et al.; Glaxo-SmithKline, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.o. Box 1539, King of Prussia, PA 19406-0939 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
30 December 2009

(54) Title: METHODS OF TREATMENT

(57) Abstract: The present invention relates generally to the methods for the treatment and diagnosis of conditions mediated by IL-5 and excess eosinophil production, and more specifically to mAbs, Fabs, chimeric and humanized antibodies. More particularly, the present invention relates generally to the treatment of eosinophilic bronchitis with an anti- IL-5 antibody or fragment thereof.

WO 2009/120927 A3